Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Willfact (von Willebrand factor concentrate) during ECMO in adults
2017-003036-37Phase 2Terminated
- Sponsor
- Tirol Kliniken
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in von Willebrand disease (VWD), acquired von Willebrand syndrome (AVWS) and bleeding diathesis comparing Willfact with Placebo (2 arms). Primary endpoint: Red blood cell concentrate transfusion requirement. Started Sep 2017; status: terminated.
02
Drugs
von Willebrand factor human
03
Conditions
von Willebrand disease (VWD)acquired von Willebrand syndrome (AVWS)bleeding diathesis
Beyond the preview
Go deeper on 2017-003036-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003036-37.